Seoul Pharma Co., Ltd.

As of March 31, 2026, Seoul Pharma Co., Ltd. carries a market capitalization of 30.90B, placing it among publicly traded companies globally. Its enterprise value stands at 29.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Seoul Pharma Co., Ltd. has 11.66M shares outstanding.

As of March 31, 2026, Seoul Pharma Co., Ltd. trades at a trailing price-to-earnings ratio of 42.56. The price-to-sales ratio is 0.60, and the price-to-book ratio stands at 0.76.

As of March 31, 2026, Seoul Pharma Co., Ltd. trades at an EV/EBITDA multiple of 22.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 29.99B versus a market cap of 30.90B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Seoul Pharma Co., Ltd. maintains a current ratio of 2.38, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Seoul Pharma Co., Ltd. posted a return on equity (ROE) of 1.80, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 1.02, measuring how efficiently the asset base is converted into earnings. The company generates approximately 333.29M in revenue per employee across its workforce of 154.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.73 indicates how many times Seoul Pharma Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Seoul Pharma Co., Ltd. recorded an income tax benefit of -49.60M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 676.29M, leaving 725.89M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Seoul Pharma Co., Ltd.'s stock has declined approximately 40.73% over the past 52 weeks. The 50-day moving average sits at 1,946.64, while the 200-day moving average is 2,429.15.

Over the twelve months ended March 31, 2026, Seoul Pharma Co., Ltd. generated 51.33B in revenue and converted that into 725.89M in net income, yielding earnings per share of 62.26. EBITDA reached 1.31B, while operating income came in at -1.35B.

As of March 31, 2026, Seoul Pharma Co., Ltd. holds 18.13B in cash and equivalents against 17.22B in total debt, resulting in a net debt position of -3.13B. Total book value stands at 40.86B, with working capital of 19.48B providing operational flexibility.

Seoul Pharma Co., Ltd. produced 10.95B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -942.22M in capital expenditures, free cash flow totaled 10.01B - equivalent to 858.57 per share.

Over the twelve months ended March 31, 2026, Seoul Pharma Co., Ltd. posted a gross margin of 60.18, reflecting its pricing power and cost economics. The operating margin of -2.63 and net profit margin of 1.41 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 32.40, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -4.42, meaning Seoul Pharma Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Seoul Pharma Co., Ltd.'s most recent stock split took place on April 16, 2004 with a 1:2 split ratio.

As of March 31, 2026, Seoul Pharma Co., Ltd. has an Altman Z-Score of 1.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.